혈액투석 및 복막투석 시장 예측(2026-2032년)

The Hemodialysis & Peritoneal Dialysis Market is projected to grow by USD 161.73 billion at a CAGR of 7.74% by 2032.

Hemodialysis and peritoneal dialysis remain core renal replacement therapies for people living with kidney failure, particularly as chronic kidney disease is increasingly linked to diabetes, hypertension, cardiovascular disease, aging populations, and delayed nephrology referral. Hemodialysis is commonly delivered through in-center care models using dialyzers, vascular access, water treatment systems, and trained clinical teams, while peritoneal dialysis enables home-based treatment through the peritoneal membrane, dialysate exchanges, sterile consumables, and patient self-management. The sector is shaped by clinical priorities such as dialysis adequacy, infection prevention, fluid management, anemia control, vascular access preservation, residual kidney function, and quality of life. Health systems are also placing greater emphasis on home dialysis adoption, patient education, remote patient monitoring, interoperable electronic health records, and value-based kidney care to reduce avoidable hospitalizations and improve continuity across pre-dialysis, dialysis, transplant, and palliative pathways. Regulatory oversight, reimbursement policy, workforce availability, and supply chain resilience remain decisive factors influencing treatment access and service configuration across mature and emerging healthcare systems.

Transformative Shifts in the Dialysis Landscape

The dialysis landscape is undergoing structural change as care delivery shifts from facility-centered treatment toward more flexible, patient-centered kidney care. Home hemodialysis and peritoneal dialysis are gaining policy attention because they can reduce travel burden, support individualized schedules, and improve autonomy when patients receive appropriate training and clinical follow-up. At the same time, in-center hemodialysis continues to be essential for patients with complex comorbidities, limited home support, urgent-start requirements, or contraindications to peritoneal dialysis. Transformation is also visible in infection control protocols, biocompatible membranes, high-flux hemodialysis, hemodiafiltration approaches, automated peritoneal dialysis, catheter design, vascular access surveillance, and water quality standards. Workforce shortages in nephrology nursing and technician roles are accelerating interest in automation, standardized workflows, telehealth-enabled support, and remote troubleshooting. Sustainability has also become a strategic consideration, as dialysis is resource-intensive in water, energy, packaging, and logistics. Providers and policymakers are therefore balancing clinical outcomes, affordability, environmental stewardship, and equitable access while redesigning services for a rising kidney disease burden.

Cumulative Impact of Artificial Intelligence on Dialysis Care

Artificial intelligence is becoming increasingly relevant across hemodialysis and peritoneal dialysis by strengthening decision support, risk stratification, operational efficiency, and personalized care. In clinical settings, AI-enabled analytics can help identify patients at elevated risk of intradialytic hypotension, vascular access dysfunction, fluid overload, hospitalization, technique failure, and peritonitis when integrated with validated clinical data and clinician oversight. For hemodialysis operations, machine learning can support scheduling optimization, predictive maintenance, dialysate and ultrafiltration pattern review, and early detection of treatment anomalies. In peritoneal dialysis, connected cyclers and remote monitoring platforms can generate actionable insights on missed exchanges, drain issues, dwell patterns, ultrafiltration trends, and adherence signals. The cumulative impact of AI is strongest when deployed as an assistive layer rather than a replacement for nephrologists and dialysis nurses. Its success depends on data quality, interoperability, algorithm transparency, cybersecurity, bias mitigation, regulatory compliance, and patient consent. As kidney care becomes more digitally connected, AI can improve care coordination between dialysis centers, home programs, laboratories, hospitals, and transplant teams without diminishing the importance of individualized clinical judgment.

Key Regional Insights Across Global Dialysis Markets

Asia-Pacific is a highly dynamic dialysis region because of large populations, rising diabetes and hypertension prevalence, expanding healthcare infrastructure, and government efforts to improve kidney care access in urban and secondary cities. Countries such as China, India, Japan, South Korea, and Australia show different dialysis models, with Japan and South Korea maintaining advanced in-center hemodialysis capabilities, Australia supporting home dialysis pathways, and China and India expanding capacity while addressing affordability and geographic disparities. North America is characterized by established reimbursement structures, broad dialysis clinic networks, growing emphasis on home dialysis, and policy-driven efforts to improve kidney care coordination, particularly in the United States and Canada. Latin America faces uneven access across public and private systems, with Brazil and Mexico serving as major dialysis hubs while rural access, transplant availability, and out-of-pocket costs remain critical challenges. Europe benefits from strong clinical guidelines, national renal registries, established nephrology societies, and increasing interest in home therapies, though uptake varies by country depending on reimbursement, patient education, and workforce capacity. The Middle East is expanding renal care infrastructure through public hospital investment and specialty centers, with GCC countries focusing on advanced technologies and chronic disease programs, while conflict-affected areas face continuity-of-care risks. Africa continues to experience significant access barriers due to limited nephrology workforce, affordability constraints, infrastructure gaps, and late diagnosis, making prevention, early detection, and sustainable dialysis delivery essential regional priorities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are expanding dialysis access against a backdrop of diabetes-driven kidney disease, urban-rural disparities, and variable reimbursement coverage, with Singapore, Malaysia, and Thailand showing more structured kidney care programs while other markets continue to strengthen public financing and clinical capacity. The GCC is investing in advanced hospital infrastructure, dialysis center expansion, and specialist workforce development, supported by high noncommunicable disease prevalence and national health transformation programs that prioritize chronic disease management. The European Union benefits from harmonized medical device regulation, cross-border clinical collaboration, mature renal registries, and kidney care guidelines, while individual member states differ in home dialysis penetration, procurement models, and reimbursement incentives. BRICS countries collectively represent diverse dialysis realities: China and India face large patient populations and capacity expansion needs, Brazil has a significant publicly supported dialysis system, Russia maintains hospital-linked renal services across a vast geography, and South Africa reflects broader African challenges around affordability and unequal access. G7 countries generally have advanced nephrology systems, established regulatory oversight, renal registries, and high adoption of quality standards, yet they continue to confront aging populations, workforce shortages, and the need to expand home-based therapy where clinically appropriate. NATO member countries overlap significantly with high-income renal care systems in North America and Europe, where resilience planning, supply chain continuity, cybersecurity for connected devices, and emergency preparedness are increasingly important for dialysis services that must operate without interruption during public health crises, natural disasters, or geopolitical disruptions.

Key Country Insights in Hemodialysis and Peritoneal Dialysis

The United States has one of the most developed dialysis infrastructures, supported by federal coverage for kidney failure care, a large in-center network, and policy initiatives encouraging home dialysis and transplant-oriented care coordination. Canada emphasizes universal health coverage, provincial kidney programs, home therapy education, and quality improvement, though access can vary across remote and Indigenous communities. Mexico is working to expand access amid a high burden of diabetes and mixed public-private coverage, while Brazil operates one of Latin America's most significant dialysis systems and continues to address regional inequities and transplant pathway constraints. The United Kingdom supports renal services through national health structures, quality registries, and home dialysis promotion, while Germany maintains strong specialist capacity, advanced hemodialysis infrastructure, and high clinical standardization. France combines robust reimbursement with established nephrology networks and patient-centered modality planning, whereas Russia manages dialysis access across a geographically dispersed population with regional differences in infrastructure. Italy and Spain maintain mature dialysis programs, strong transplant integration, and growing attention to home therapies, aging patients, and multimorbidity management. China is expanding dialysis capacity through hospital networks and health policy reforms, while India faces substantial unmet need, affordability pressures, and expanding public insurance support in several states. Japan is recognized for high-quality hemodialysis practices, long patient survival experience, and rigorous treatment standards, although home dialysis uptake remains comparatively limited. Australia has a strong home dialysis culture supported by renal networks and remote-care models, while South Korea combines advanced hospital-based dialysis capacity, digital health readiness, and a high chronic disease burden that sustains demand for comprehensive kidney care.

Actionable Recommendations for Dialysis Industry Leaders

Industry leaders should prioritize modality-neutral kidney care pathways that help patients make informed choices among in-center hemodialysis, home hemodialysis, peritoneal dialysis, transplantation, and conservative care where appropriate. Investment in patient education, caregiver support, multilingual training materials, and early nephrology referral can improve therapy preparedness and reduce urgent dialysis starts. Providers should strengthen infection prevention, vascular access planning, peritonitis reduction programs, and standardized quality metrics while embedding remote monitoring and telehealth into home dialysis operations. Manufacturers and service organizations should focus on device usability, automation, cybersecurity, interoperability, water and energy efficiency, and resilient supply chains for dialyzers, concentrates, fluids, catheters, and consumables. Policymakers and payers can improve access by aligning reimbursement with outcomes, supporting home therapy infrastructure, funding workforce development, and reducing financial barriers for low-income and rural patients. Leaders should also build emergency preparedness protocols for dialysis continuity during disasters, pandemics, power interruptions, logistics disruptions, and cybersecurity incidents.

Research Methodology for Dialysis Industry Analysis

The research approach combines validated secondary sources, clinical guidelines, regulatory documents, renal registry publications, peer-reviewed nephrology literature, public health datasets, reimbursement policies, and expert interpretation across care delivery models. Evidence is assessed for source credibility, recency, geographic relevance, methodological transparency, and consistency across multiple references. Analysis of hemodialysis and peritoneal dialysis considers clinical outcomes, modality access, reimbursement design, infrastructure readiness, device regulation, workforce capacity, patient experience, digital health adoption, and health equity. Regional, group, and country-level insights are cross-checked against official health authority publications, kidney disease registries, international nephrology organizations, and medical device regulatory frameworks. The methodology avoids unsupported projections and distinguishes clearly between observed trends, policy developments, clinical evidence, and operational implications. Triangulation across quantitative healthcare indicators and qualitative expert interpretation provides a balanced view of dialysis access, innovation, and care transformation.

Conclusion: Advancing Patient-Centered Dialysis Care

Hemodialysis and peritoneal dialysis are central to kidney failure management and are evolving through home-based care, digital monitoring, AI-enabled analytics, improved device design, and stronger quality standards. The most important industry themes extend beyond treatment capacity to include equitable access, patient autonomy, infection prevention, workforce resilience, reimbursement alignment, sustainability, and continuity of care. Regional differences remain substantial, with high-income systems focusing on optimization and home therapy expansion, while emerging markets prioritize affordability, infrastructure, and earlier diagnosis. AI and connected care technologies can improve dialysis safety and personalization when implemented with strong governance and clinical accountability. Organizations that combine evidence-based clinical practice, resilient operations, patient-centered education, and responsible innovation will be best positioned to support safer, more accessible, and more sustainable kidney care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hemodialysis & Peritoneal Dialysis Market, by Treatment Type

• 7.1. Introduction
• 7.2. Hemodialysis
• 7.3. Peritoneal Dialysis
  • 7.3.1. Automated Peritoneal
  • 7.3.2. Continuous Ambulatory Peritoneal

8. Hemodialysis & Peritoneal Dialysis Market, by Modality

• 8.1. Introduction
• 8.2. Home
  • 8.2.1. Assisted Care
  • 8.2.2. Self Care
• 8.3. In Center

9. Hemodialysis & Peritoneal Dialysis Market, by Technology

• 9.1. Introduction
• 9.2. Conventional Hemodialysis
• 9.3. Online Hemodiafiltration
  • 9.3.1. Mixed Flow
  • 9.3.2. Substitution Flow

10. Hemodialysis & Peritoneal Dialysis Market, by Product Type

• 10.1. Introduction
• 10.2. Concentrates Fluids
• 10.3. Dialysis Machines
• 10.4. Dialyzers
  • 10.4.1. High Flux
  • 10.4.2. Low Flux
• 10.5. Monitoring Systems
• 10.6. Tubing Sets

11. Hemodialysis & Peritoneal Dialysis Market, by Patient Type

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. Hemodialysis & Peritoneal Dialysis Market, by End User

• 12.1. Introduction
• 12.2. Dialysis Centers
• 12.3. Home Care Settings
• 12.4. Hospitals
• 12.5. Specialty Clinics

13. Hemodialysis & Peritoneal Dialysis Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Hemodialysis & Peritoneal Dialysis Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Hemodialysis & Peritoneal Dialysis Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Allmed Medical Products Co., Ltd.
• 17.2. AngioDynamics, Inc.
• 17.3. Asahi Kasei Corporation
• 17.4. B. Braun SE
• 17.5. Baxter International, Inc.
• 17.6. Becton, Dickinson and Company
• 17.7. DaVita Inc.
• 17.8. Dialife SA
• 17.9. Diaverum AB
• 17.10. Evoqua Water Technologies LLC
• 17.11. Fresenius Medical Care AG & Co. KGaA
• 17.12. Hemoclean Co. Ltd.
• 17.13. Jafron Biomedical Co., Ltd.
• 17.14. JMS Co., Ltd.
• 17.15. Medica S.p.A.
• 17.16. Medtronic PLC
• 17.17. Nikkiso Co., Ltd.
• 17.18. Nipro Corporation
• 17.19. NxStage Medical Inc.
• 17.20. Rajsun Innovations LLP
• 17.21. Rockwell Medical Inc.
• 17.22. SB-KAWASUMI LABORATORIES, INC.
• 17.23. STERIS Group
• 17.24. Toray Medical Co., Ltd.
• 17.25. Trivitron Healthcare